- Home
- GOVX vs BREA Comparison
GOVX vs BREA Comparison
Compare GOVX & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- BREA
- Stock Information
- Founded
- GOVX 2001
- BREA 2022
- Country
- GOVX United States
- BREA Ireland
- Employees
- GOVX N/A
- BREA N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- GOVX Health Care
- BREA Consumer Discretionary
- Exchange
- GOVX Nasdaq
- BREA Nasdaq
- Market Cap
- GOVX 15.5M
- BREA 13.6M
- IPO Year
- GOVX N/A
- BREA 2023
- Fundamental
- Price
- GOVX $0.95
- BREA $6.88
- Analyst Decision
- GOVX Strong Buy
- BREA
- Analyst Count
- GOVX 5
- BREA 0
- Target Price
- GOVX $12.40
- BREA N/A
- AVG Volume (30 Days)
- GOVX 1.5M
- BREA 18.5K
- Earning Date
- GOVX 08-05-2025
- BREA 01-03-2025
- Dividend Yield
- GOVX N/A
- BREA N/A
- EPS Growth
- GOVX N/A
- BREA N/A
- EPS
- GOVX N/A
- BREA N/A
- Revenue
- GOVX $5,591,576.00
- BREA $2,988,009.00
- Revenue This Year
- GOVX N/A
- BREA N/A
- Revenue Next Year
- GOVX N/A
- BREA N/A
- P/E Ratio
- GOVX N/A
- BREA N/A
- Revenue Growth
- GOVX N/A
- BREA 151.51
- 52 Week Low
- GOVX $0.73
- BREA $5.00
- 52 Week High
- GOVX $11.18
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- GOVX 46.22
- BREA 96.66
- Support Level
- GOVX $0.85
- BREA $0.66
- Resistance Level
- GOVX $1.39
- BREA $0.79
- Average True Range (ATR)
- GOVX 0.15
- BREA 0.20
- MACD
- GOVX -0.02
- BREA 0.39
- Stochastic Oscillator
- GOVX 18.52
- BREA 84.50
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.